HealthyNCT05939336
MOS Prebiotic Potential in Older Adults
A study testing Mannooligosaccharides yeast extract in people with Healthy, run by University of Florida at 1 site in United States.
Trial summary
Mannooligosaccharides (MOS) derived from baker's yeast may have prebiotic properties such as improving gastrointestinal function. The aims of this study are to determine the effect of MOS on gastrointestinal function and symptoms and fecal microbiota in older adults. Read more about this study
- Who is it for?
- Ages 50 to 99 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy
- What is being tested?
- Mannooligosaccharides yeast extract
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 22 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Aug 2023to 30 Sep 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 99 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Adults 50-99 years of age.
- Able to provide written informed consent in English.
- Willingness to complete all study procedures
- Healthy or diagnoses with Parkinson's or multiple system atrophy
Who cannot join
- Yeast allergy.
- Self-reported kidney disease.
- Elite athletes or long-distance runners.
- Use of antibiotic drugs (e.g., neomycin, rifaximin) within 1 month of the screening visit.
- Current use of laxatives or antidiarrheal medications.
- Use of other investigational products within 3 months of the screening visit.
Show all 10Show fewer
- Previously or currently being treated for any intestinal disease or condition, including IBS, Crohn's disease, ulcerative colitis, celiac disease, or gastrointestinal cancer (self-report).
- Previous gastrointestinal surgery (e.g., gastric bypass, fundoplication, bowel resection)
- Current cancer treatment
- Currently pregnant
Trial locations and contacts
1 site in 1 country.
United States1 site
Food Science and Human Nutrition Department, University of Florida
Gainesville, Florida, 32611
About this study
Official title: The Prebiotic Potential of a Yeast Cell Wall Fraction Containing Mannooligosaccharides and β-glucans.
Mannooligosaccharides (MOS) derived from baker's yeast may have prebiotic properties such as improving gastrointestinal function. The aims of this study are to determine the effect of MOS on gastrointestinal function and symptoms and fecal microbiota in older adults.
Read the detailed description
Novel prebiotics with specific microbiome targets and without adverse gastrointestinal symptoms are needed for the exploration of health benefits. This is a 3-week, open-label pilot study designed to evaluate the effect of 15 g per day of yeast-derived mannooligosaccharides on gastrointestinal symptoms, stool frequency, fecal microbiome, and urinary metabolites.
- Conditions
- Healthy
- Being tested
- Mannooligosaccharides yeast extract
- Keywords
- Healthy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Mannooligosaccharides yeast extractDietary supplement
15 g per day of mannooligosaccharide yeast extract.
| Study group | Role | What they receive |
|---|---|---|
| Mannooligosaccharides | Experimental | Mannooligosaccharides yeast extract Receives: Dietary Supplement: Mannooligosaccharides yeast extract |
What is being measured
The primary outcome is the main question the study is designed to answer.
Mean daily rating of gastrointestinal symptoms
Change from baseline mean sum of daily mean rating from 0 (no symptom) to 3 (severe symptoms)
Measured: 14 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Jul 2023
- Study start1 Aug 2023
- Primary completion28 Feb 2024
- Study completion30 Sep 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for HealthyStudies of the same condition, open and under way.
- More trials run by University of FloridaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 22 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Florida
- Sponsor type
- University, hospital or other
- Collaborators
- Lallemand Bio-Ingredients
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05939336
- Sponsor's protocol ID
- IRB202301046
- Status last verified
- Jan 2026
- First submitted
- 3 Jul 2023
- Last updated
- 7 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Moreno ML, Abbeele PVD, Baudot A, Tompkins TA, Taft DH, Yao R, Auger J, Colee J, Dahl WJ. Yeast mannans promote laxation and specifically modulate microbiota composition in older adults: An open-label pilot study. Nutr Res. 2025 Apr;136:15-27. doi: 10.1016/j.nutres.2025.02.004. Epub 2025 Feb 26.
PubMed 40117931
Study at a glance
From the registry record, last updated by the sponsor on 7 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Prebiotic Potential of a Yeast Cell Wall Fraction Containing Mannooligosaccharides and β-glucans.
- ClinicalTrials.gov ID
- NCT05939336
- Acronym / sponsor ID
- IRB202301046
- Conditions
- Healthy
- Keywords
- Healthy
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 22 participants (actual)
- Lead sponsor
- University of FloridaUniversity, hospital or other
- Collaborators
- Lallemand Bio-Ingredients
- Study start
- 1 Aug 2023 (actual)
- Primary completion
- 28 Feb 2024 (actual)
- Study completion
- 30 Sep 2026 (actual)
- First posted
- 11 Jul 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Mannooligosaccharides (MOS) derived from baker's yeast may have prebiotic properties such as improving gastrointestinal function. The aims of this study are to determine the effect of MOS on gastrointestinal function and symptoms and fecal microbiota in older adults.
Detailed description
Novel prebiotics with specific microbiome targets and without adverse gastrointestinal symptoms are needed for the exploration of health benefits. This is a 3-week, open-label pilot study designed to evaluate the effect of 15 g per day of yeast-derived mannooligosaccharides on gastrointestinal symptoms, stool frequency, fecal microbiome, and urinary metabolites.
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Mannooligosaccharides | Experimental | Dietary Supplement: Mannooligosaccharides yeast extractMannooligosaccharides yeast extract |
Who may qualify
- Ages
- 50 to 99 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Adults 50-99 years of age.
- Able to provide written informed consent in English.
- Willingness to complete all study procedures
- Healthy or diagnoses with Parkinson's or multiple system atrophy
Key exclusion criteria (10 listed)
- Yeast allergy.
- Self-reported kidney disease.
- Elite athletes or long-distance runners.
- Use of antibiotic drugs (e.g., neomycin, rifaximin) within 1 month of the screening visit.
- Current use of laxatives or antidiarrheal medications.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Mannooligosaccharides yeast extract15 g per day of mannooligosaccharide yeast extract. | Dietary supplement | Mannooligosaccharides |
Primary outcome
Mean daily rating of gastrointestinal symptoms
Time frame: 14 days
Change from baseline mean sum of daily mean rating from 0 (no symptom) to 3 (severe symptoms)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Oct 2026.
- Derived from this study: PubMed 40117931Moreno ML, Abbeele PVD, Baudot A, Tompkins TA, Taft DH, Yao R, Auger J, Colee J, Dahl WJ. Yeast mannans promote laxation and specifically modulate microbiota composition in older adults: An open-label pilot study. Nutr Res. 2025 Apr;136:15-27. doi: 10.1016/j.nutres.2025.02.004. Epub 2025 Feb 26.
- Individual participant dataSharing planned: No
Related trials for Healthy
RecruitingPhase 3
A Study to Learn About the Safety of an Expanded Pneumococcal Vaccine in Healthy Infants
Pneumococcal Disease
RecruitingObservational study
Development of Magnetic Resonance Imaging Techniques for Studying Mood and Anxiety Disorders
Mood Disorders, Anxiety Disorders
Not yet recruiting
Positron Emission Tomography and Organ-Specific Changes in Participants Co-Enrolled in NIH Studies of Plasmodium Vivax Controlled Human Malaria Infection
Healthy Volunteer, Malaria
Not yet recruiting
Evaluating the Healthy Families PrEP Program for Women at Risk for HIV
HIV, Pregnancy
RecruitingPhase 1
A Single Ascending Dose Study of DTI-117 Given Intramuscularly in Healthy Participants.
Healthy Adult
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Mannooligosaccharides yeast extract in people with Healthy, run by University of Florida at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 7 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mean daily rating of gastrointestinal symptoms (time frame: 14 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05939336, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Oct 2026.